Systematic mediastinal lymphadenectomy or mediastinal lymph node sampling in patients with pathological stage I NSCLC: a meta-analysis

World J Surg. 2015 Feb;39(2):410-6. doi: 10.1007/s00268-014-2804-8.

Abstract

Background: To evaluate the evidence comparing systematic mediastinal lymphadenectomy (SML) and mediastinal lymph node sampling (MLS) in the treatment of pathological stage I NSCLC using meta-analytical techniques.

Methods: A literature search was undertaken until January 2014 to identify the comparative studies evaluating 1-, 3-, and 5-year survival rates. The pooled odds ratios (OR) and the 95 % confidence intervals (95 % CI) were calculated with either the fixed or random effect models.

Results: One RCT study and four retrospective studies were included in our meta-analysis. These studies included a total of 711 patients: 317 treated with SML, and 394 treated with MLS. The SML and the MLS did not demonstrate a significant difference in the 1-year survival rate. There were significant statistical differences between the 3-year (P = 0.03) and 5-year survival rates (P = 0.004), which favored SML.

Conclusions: This meta-analysis suggests that in pathological stage I NSCLC, the MLS can get the similar outcome to the SML in terms of 1-year survival rate. However, the SML is superior to MLS in terms of 3- and 5-year survival rates.

Publication types

  • Comparative Study
  • Meta-Analysis
  • Review

MeSH terms

  • Biopsy
  • Carcinoma, Non-Small-Cell Lung / secondary*
  • Carcinoma, Non-Small-Cell Lung / surgery
  • Humans
  • Lung Neoplasms / pathology*
  • Lung Neoplasms / surgery
  • Lymph Node Excision / mortality*
  • Lymph Nodes / pathology*
  • Lymph Nodes / surgery*
  • Lymphatic Metastasis
  • Mediastinum
  • Neoplasm Staging
  • Survival Rate